


# PROGRAM

PROGRAM

## AMERICAN PSYCHIATRIC ASSOCIATION 2007 ANNUAL MEETING



**SAN DIEGO, CA ♦ MAY 19-24, 2007**



## AMERICAN PSYCHIATRIC ASSOCIATION CONTINUING MEDICAL EDUCATION POLICY ON FULL DISCLOSURE

The American Psychiatric Association requires disclosure, by presenters at CME activities, of any significant financial or other affiliation with commercial organization(s) regulated by the Food and Drug Administration, which may have a direct or indirect interest in the subject matter of the scientific program. A "financial interest" may include, but is not limited to, being a shareholder in the organization; being on retainer with the organization; or having research or honoraria paid by the organization. An "affiliation" may include holding a position on an advisory committee or some other role or benefit to a supporting organization.

Under the ACCME Standards for Commercial Support that were in effect when the 2007 Annual Meeting was planned, the existence of such relationships does not necessarily constitute a conflict of interest; but the prospective audience must be informed of the presenter's affiliation with every commercial supporter by an acknowledgement in the printed program and verbal or visual disclosure to participants at the session (disclosure by slide or overhead is required if audiovisual equipment is used for the presentation). This policy is intended to openly identify any potential conflict(s) so that members of the audience in an educational activity are able to form their own judgments about the presentation. The APA also requires verbal disclosure of discussion of unlabeled uses of a commercial product or investigational use of a product not yet approved for this purpose.

The list of presenters below have indicated that either they or an immediate family member has a significant interest or other affiliation with a commercial supporter of this meeting and/or with the manufacturer(s) of a commercial product(s) and/or provider of commercial services(s). The presenter's name and the company's name are listed, along with the page number the presenter appears on in this *Program Book*. The nature of the presenter's relationship with the disclosed company is indicated by the following code: consultant or advisory board<sup>1</sup>, full-time employment<sup>2</sup>, research/grant support<sup>3</sup>, speakers' bureau<sup>4</sup>, stock or other financial options<sup>5</sup>, other financial or business relationships<sup>6</sup>. If a number has not been assigned, the presenter has not disclosed the relationship to the company.

The second list of presenters, beginning on page \*\*\*\*, have indicated neither they nor an immediate family member has any significant relationship to disclose. Voting member of the Board of Trustees, Assembly officers, and member of the Scientific Program Committee cannot receive honoraria or travel reimbursement for participating in Industry-Supported Symposia.

Presenter	Manufacturer(s)
Gene G. Abel, M.D.	Abel Screening, Inc. <sup>6</sup>
Hagop S. Akiskal, M.D.	Abbott Laboratories, Inc. <sup>5</sup> ; AstraZeneca Pharmaceuticals LP <sup>5</sup> ; Bristol-Myers Squibb Company <sup>3,5</sup> ; Eli Lilly and Company <sup>3,5</sup> ; GlaxoSmithKline <sup>1,3,5</sup> ; Sanofi-Aventis <sup>1,5</sup>
Michael H. Allen, M.D.	Abbott Laboratories, Inc. <sup>1,3</sup> ; Alexza MDC <sup>1</sup> ; AstraZeneca Pharmaceuticals LP <sup>1,3</sup> ; Bristol-Myers Squibb Company <sup>1,3</sup> ; Eli Lilly and Company <sup>3</sup> ; Janssen Pharmaceutica Products, LP <sup>3</sup> ; Pfizer Inc. <sup>1,3</sup>
Jonathan E. Alpert, M.D.	Abbott Laboratories, Inc. <sup>3</sup> ; Alkermes, Inc. <sup>3</sup> ; Aspect Medical Systems <sup>3</sup> ; AstraZeneca Pharmaceuticals LP <sup>3</sup> ; Bristol-Myers Squibb Company <sup>3</sup> ; Cephalon, Inc. <sup>3</sup> ; Cyberonics, Inc. <sup>3</sup> ; Eli Lilly and Company <sup>1,3,5</sup> ; Forest Laboratories, Inc. <sup>3</sup> ; GlaxoSmithKline <sup>3</sup> ; Johnson & Johnson <sup>3</sup> ; Johnson and Johnson Pharmaceutical Research and Development <sup>3</sup> ; Lichtwer Pharma GmbH <sup>3</sup> ; Lorex Pharmaceuticals <sup>3</sup> ; National Alliance for Research in Schizophrenia and Depression <sup>3</sup> ; National Institute of Mental Health <sup>3</sup> ; Novartis Pharmaceuticals Corporation <sup>3</sup> ; Organon Pharmaceuticals Inc. <sup>3,5</sup> ; PamLab <sup>1,3</sup> ; Pfizer Inc. <sup>3</sup> ; Pharmavite <sup>1,3</sup> ; Roche Pharmaceuticals <sup>3</sup> ; Sanofi/Synthelabo <sup>3</sup> ; Sanofi-Aventis <sup>3</sup> ; Solvay Pharmaceuticals, Inc. <sup>3</sup> ; Wyeth-Ayerst Laboratories <sup>3</sup>
Lori L. Altshuler, M.D.	Abbott Laboratories, Inc. <sup>3,4</sup> ; AstraZeneca Pharmaceuticals LP <sup>4,5</sup> ; Bristol-Myers Squibb Company <sup>1,4,5</sup> ; Eli Lilly and Company <sup>1,4,5</sup> ; Forest Laboratories, Inc. <sup>1,4</sup> ; GlaxoSmithKline <sup>4,5</sup> ; Pfizer Inc. <sup>1,4</sup> ; Wyeth Pharmaceuticals <sup>4</sup>
Sonia Ancoli-Israel, Ph.D.	Acadia Pharmaceuticals Inc. <sup>1</sup> ; Cephalon, Inc. <sup>1,5</sup> ; King Pharmaceuticals, Inc. <sup>1,5</sup> ; Merck & Co., Inc. <sup>1</sup> ; Neurocrine Biosciences Inc. <sup>1,5</sup> ; Neurogen Corporation <sup>1</sup> ; NIH Institute <sup>3</sup> ; Pfizer Inc. <sup>1,5</sup> ; Sanofi-Aventis <sup>1,5</sup> ; Sepracor, Inc. <sup>1,5</sup> ; Takeda Pharmaceuticals America, Inc. <sup>1,5</sup>
Raymond F. Anton, M.D.	Alkermes, Inc. <sup>1</sup> ; AstraZeneca Pharmaceuticals LP <sup>1</sup> ; Bristol-Myers Squibb Company <sup>3</sup> ; Cephalon, Inc. <sup>1,5</sup> ; Forest Laboratories, Inc. <sup>1,3</sup> ; Ortho-McNeil Pharmaceutical, Inc. <sup>3</sup> ; Pfizer Inc. <sup>3</sup>
William J. Apfeldorf, M.D.	Abbott Laboratories, Inc. <sup>5</sup> ; AstraZeneca Pharmaceuticals LP <sup>5</sup> ; Eisai Inc. <sup>3</sup> ; Eli Lilly and Company <sup>5</sup> ; Forest Laboratories, Inc. <sup>1,5</sup> ; Janssen Pharmaceutica Products, LP <sup>5</sup> ; Pfizer Inc. <sup>5</sup> ; Wyeth Pharmaceuticals <sup>5</sup>
Lesley M. Arnold, M.D.	Cypress Bioscience Inc. <sup>1,3</sup> ; Eli Lilly and Company <sup>1,3,5</sup> ; Forest Laboratories, Inc. <sup>1</sup> ; Pfizer Inc. <sup>1,3,5</sup> ; Sanofi-Aventis <sup>1,3</sup> ; Sepracor, Inc. <sup>1</sup> ; Wyeth Pharmaceuticals <sup>1,3</sup>
Alan Axelson, M.D.	Eli Lilly and Company <sup>5</sup> ; Novartis Pharmaceuticals Corporation <sup>5</sup> ; Shire Pharmaceuticals Group plc. <sup>5</sup>
Marion A. Becker, Ph.D.	Eli Lilly and Company <sup>3</sup>
Julian Beezhoid, M.B.Ch.B.	AstraZeneca Pharmaceuticals LP <sup>5</sup> ; Bristol-Myers Squibb Company <sup>5</sup> ; Eli Lilly and Company <sup>5</sup> ; Janssen-Cilag <sup>5</sup>
Bernard D. Beitman, M.D.	Bristol-Myers Squibb Company <sup>5</sup>
Ruth M. Benca, M.D.	GlaxoSmithKline <sup>1</sup> ; Neurocrine Biosciences Inc. <sup>1,5</sup> ; Pfizer Inc. <sup>1,5</sup> ; Sanofi-Aventis <sup>1,5</sup> ; Sepracor, Inc. <sup>1,5</sup> ; Takeda Pharmaceuticals America, Inc. <sup>1,5</sup> ; Wyeth Pharmaceuticals <sup>5</sup>
Donna S. Bender, Ph.D.	National Institute of Mental Health <sup>3</sup>
Susan R. Bergeson, M.B.A.	Abbott Laboratories, Inc. <sup>3</sup>



Presenter	Manufacturer(s)
Raymond A. Faber	Bristol-Myers Squibb Company <sup>5</sup> ; Cephalon, Inc. <sup>5</sup> ; Forest Laboratories, Inc. <sup>5</sup>
Andrea Fagiolini, M.D.	Bristol-Myers Squibb Company <sup>1</sup> ; GlaxoSmithKline <sup>1</sup> ; Merck & Co., Inc. <sup>3</sup> ; Pfizer Inc. <sup>3</sup>
Warachal E. Faison, M.D.	Bristol-Myers Squibb Company <sup>1,5</sup> ; Forest Laboratories, Inc. <sup>1,5</sup> ; GlaxoSmithKline <sup>4</sup> ; Janssen Pharmaceutica Products, LP <sup>1,5</sup> ; National Institute of Mental Health <sup>3</sup> ; National Institute on Aging <sup>3</sup> ; Organon Pharmaceuticals Inc. <sup>3</sup> ; Otsuka America Pharmaceutical, Inc. <sup>1,5</sup> ; Pfizer Inc. <sup>1,3,5</sup>
Stephen V. Faraone, Ph.D.	Cephalon, Inc. <sup>1,5</sup> ; Eli Lilly and Company <sup>1,3,5</sup> ; McNeil Consumer Healthcare <sup>1,3,5</sup> ; National Foundation for Mental Health <sup>3</sup> ; National Institute of Child Health and Human Development <sup>3</sup> ; National Institute of Mental Health <sup>3</sup> ; National Institute of Neurological Disorders and Stroke <sup>3</sup> ; National Institute on Drug Abuse <sup>3</sup> ; Noven Pharmaceuticals, Inc. <sup>1</sup> ; Shire Pharmaceuticals Group plc. <sup>1,3,5</sup>
Maurizio Fava, M.D.	Abbott Laboratories, Inc. <sup>3</sup> ; Alkermes, Inc. <sup>3</sup> ; Aspect Medical Systems <sup>1,3</sup> ; AstraZeneca Pharmaceuticals LP <sup>1,3,5</sup> ; Bayer Corporation <sup>1</sup> ; Biovail Corporation <sup>1</sup> ; Boehringer-Ingelheim Pharmaceuticals <sup>5</sup> ; BrainCells, Inc. <sup>1</sup> ; Bristol-Myers Squibb Company <sup>1,3,5</sup> ; Cephalon, Inc. <sup>1,3,5</sup> ; Compellis Pharmaceuticals <sup>1,6</sup> ; Cypress Bioscience Inc. <sup>1</sup> ; Cypress Pharmaceuticals <sup>1</sup> ; Dov Pharmaceuticals <sup>1</sup> ; Eli Lilly and Company <sup>1,3,5</sup> ; EPIX <sup>1</sup> ; Fabre Kramer Pharmaceuticals Inc. <sup>1</sup> ; Forest Laboratories, Inc. <sup>1,3,5</sup> ; GlaxoSmithKline <sup>1,3,5</sup> ; Grunenthal GmbH <sup>1</sup> ; Janssen Pharmaceutica Products, LP <sup>1</sup> ; Jazz Pharmaceuticals, Inc. <sup>1</sup> ; Johnson and Johnson Pharmaceutical Research and Development <sup>1,3</sup> ; Knoll Pharmaceutical Company <sup>1</sup> ; Lichtwer Pharma GmbH <sup>3</sup> ; Lorex Pharmaceuticals <sup>3</sup> ; Lundbeck <sup>1</sup> ; MedAvante, Inc. <sup>1,6</sup> ; Neuronetics, Inc. <sup>1</sup> ; Novartis Pharmaceuticals Corporation <sup>1,3,5</sup> ; Nutrition 21, Inc. <sup>1</sup> ; Organon Pharmaceuticals Inc. <sup>1,3,5</sup> ; PamLab <sup>1,3</sup> ; Pfizer Inc. <sup>1,3,5</sup> ; Pharmacia & Upjohn <sup>1,3</sup> ; PharmaStar <sup>1,5</sup> ; Pharmavite <sup>1,3</sup> ; Roche Pharmaceuticals <sup>1,3</sup> ; Sanofi/Synthelabo <sup>1,3</sup> ; Sanofi-Aventis <sup>1,3</sup> ; Sepracor, Inc. <sup>1,3</sup> ; Solvay Pharmaceuticals, Inc. <sup>1,3</sup> ; Somaxon Pharmaceuticals <sup>1</sup> ; Somerset Pharmaceuticals Inc. <sup>1</sup> ; Wyeth Pharmaceuticals <sup>1,3,5</sup> ; Wyeth-Ayerst Laboratories <sup>1,3,5</sup>
Jan Fawcett, M.D.	Abbott Laboratories, Inc. <sup>1</sup> ; Eli Lilly and Company <sup>5</sup> ; National Institute of Mental Health <sup>3</sup> ; Wyeth Pharmaceuticals <sup>1</sup>
Francisco Fernandez, M.D.	Bristol-Myers Squibb Company <sup>3</sup> ; Cyberonics, Inc. <sup>3</sup> ; Esai-Pfizer <sup>3</sup> ; NIH Institute <sup>3</sup> ; Pfizer Inc. <sup>3</sup> ; Sumitomo Pharmaceuticals Co., Ltd <sup>3</sup> ; Wyeth Pharmaceuticals <sup>5</sup>
Robert L. Findling, M.D.	Abbott Laboratories, Inc. <sup>1</sup> ; AstraZeneca Pharmaceuticals LP <sup>1</sup> ; Bristol-Myers Squibb Company <sup>1</sup> ; Eli Lilly and Company <sup>1</sup> ; Forest Laboratories, Inc. <sup>1</sup> ; GlaxoSmithKline <sup>1</sup> ; Johnson and Johnson Pharmaceutical Research and Development <sup>1</sup> ; Novartis Pharmaceuticals Corporation <sup>1</sup> ; Otsuka America Pharmaceutical, Inc. <sup>1</sup> ; Pfizer Inc. <sup>1</sup> ; Sanofi-Aventis <sup>1</sup> ; Shire Pharmaceuticals Group plc. <sup>1,5</sup> ; Solvay Pharmaceuticals, Inc. <sup>1</sup> ; Wyeth Pharmaceuticals <sup>1</sup>
Naomi A. Fineberg	AstraZeneca Pharmaceuticals LP <sup>5</sup> ; Bristol-Myers Squibb Company <sup>3</sup> ; Cephalon, Inc. <sup>3</sup> ; GlaxoSmithKline <sup>1</sup>
David P. Folsom, M.D.	National Institute of Mental Health <sup>4</sup>
Timothy W. Fong, M.D.	Forest Laboratories, Inc. <sup>5</sup> ; Ortho-McNeil Pharmaceutical, Inc. <sup>3</sup> ; Reckitt-Benkiser <sup>5</sup>
Brent P. Forester, M.D.	Abbott Laboratories, Inc. <sup>3,5</sup> ; AstraZeneca Pharmaceuticals LP <sup>5</sup> ; Eli Lilly and Company <sup>5</sup> ; GlaxoSmithKline <sup>3</sup> ; Janssen Pharmaceutica Products, LP <sup>5</sup> ; Novartis Pharmaceuticals Corporation <sup>5</sup> ; Pfizer Inc. <sup>3,5</sup>
Philippe Fossati, M.D.	Eli Lilly and Company <sup>1</sup> ; Servier <sup>3</sup>
Ellen Frank, Ph.D.	Eli Lilly and Company <sup>1</sup> ; Forest Laboratories, Inc. <sup>3</sup> ; Forest Research Institute <sup>3</sup> ; Guilford Press <sup>4</sup> ; Guilford Pharmaceuticals <sup>1</sup> ; H. Lundbeck A/S, Guilford Press <sup>4</sup> ; Lundbeck <sup>1</sup> ; National Institute of Mental Health <sup>3</sup> ; Novartis Pharmaceuticals Corporation <sup>1</sup> ; Pfizer Inc. <sup>1</sup> ; Servier <sup>1</sup>
Gordon Frankle, M.D.	AstraZeneca Pharmaceuticals LP <sup>3</sup> ; Bristol-Myers Squibb Company <sup>3</sup> ; Fujisawa Pharmaceutical, Co. <sup>3</sup>
Nancy Frasure-Smith, Ph.D.	GlaxoSmithKline <sup>3</sup> ; IsodisNatura <sup>3</sup> ; Solvay Pharmaceuticals, Inc. <sup>5</sup>
Marlene P. Freeman, M.D.	Arizona Disease Control Research Commission <sup>3</sup> ; AstraZeneca Pharmaceuticals LP <sup>5</sup> ; Eli Lilly and Company <sup>5</sup> ; Forest Laboratories, Inc. <sup>3</sup> ; National Institute of Mental Health <sup>3</sup> ; Pfizer Inc. <sup>5</sup> ; Pronova Biocare <sup>3</sup> ; Reliant <sup>1</sup> ; The Institute for Mental Health Research of Arizona <sup>3</sup> ; THER-X <sup>1</sup> ; U.S. Food and Drug Administration <sup>3</sup>
Fred Frese, M.D.	Abbott Laboratories, Inc. <sup>1</sup> ; AstraZeneca Pharmaceuticals LP <sup>1</sup> ; Bristol-Myers Squibb Company <sup>1</sup> ; Eli Lilly and Company <sup>1</sup> ; Janssen Pharmaceutica Products, LP <sup>1</sup> ; Novartis Pharmaceuticals Corporation <sup>1</sup> ; Otsuka America Pharmaceutical, Inc. <sup>1</sup> ; Pfizer Inc. <sup>1</sup>
Robert D. Friedberg, Ph.D.	Guilford Publications <sup>4</sup>
Joseph I. Friedman, M.D.	Eli Lilly and Company <sup>3</sup>
Mark A. Frye, M.D.	Abbott Laboratories, Inc. <sup>1,3,5</sup> ; American Foundation for Suicide Prevention <sup>3</sup> ; AstraZeneca Pharmaceuticals LP <sup>1,5</sup> ; Bristol-Myers Squibb Company <sup>1,5</sup> ; Cephalon, Inc. <sup>5</sup> ; Eli Lilly and Company <sup>1,5</sup> ; GlaxoSmithKline <sup>1,3</sup> ; Indevus Pharmaceuticals, Inc. <sup>5</sup> ; Janssen Pharmaceutica Products, LP <sup>5</sup> ; Janssen-Cilag <sup>1</sup> ; Johnson and Johnson Pharmaceutical Research and Development <sup>1</sup> ; National Institute of Mental Health <sup>3</sup> ; Novartis Pharmaceuticals Corporation <sup>1,5</sup> ; Ortho-McNeil Pharmaceutical, Inc. <sup>1</sup> ; Otsuka America Pharmaceutical, Inc. <sup>1,3,5</sup> ; Pfizer Inc. <sup>1,3,5</sup> ; Solvay Pharmaceuticals, Inc. <sup>3</sup> ; Stanley Medical Research Institute <sup>3</sup> ; Wyeth Pharmaceuticals <sup>1</sup>
Kenneth D. Gadow, Ph.D.	Checkmate Plus <sup>6</sup>
Wolfgang Gaebel, M.D.	AstraZeneca Pharmaceuticals LP <sup>1,5</sup> ; Bristol-Myers Squibb Company <sup>1,3,5</sup> ; Eli Lilly and Company <sup>1</sup> ; GlaxoSmithKline <sup>5</sup> ; H. Lundbeck A/S <sup>1</sup> ; Janssen-Cilag <sup>1,3,5</sup> ; Lilly <sup>1,3,5</sup> ; Lundbeck <sup>1,3,5</sup> ; Novartis Pharmaceuticals Corporation <sup>1</sup> ; Sanofi-Aventis <sup>5</sup> ; Wyeth Pharmaceuticals <sup>1,3</sup>



# DISCLOSURE INDEX

Presenter	Manufacturer(s)
John M. Kane, M.D.	Abbott Laboratories, Inc. <sup>1,5</sup> ; AstraZeneca Pharmaceuticals LP <sup>1</sup> ; Bristol-Myers Squibb Company <sup>1,5</sup> ; Eli Lilly and Company <sup>1</sup> ; Janssen Pharmaceutica Products, LP <sup>1,5</sup> ; Janssen-Cilag <sup>1,5</sup> ; Johnson and Johnson Pharmaceutical Research and Development <sup>1</sup> ; Lundbeck <sup>1</sup> ; MDS Pharma Services <sup>1</sup> ; MedAvante <sup>6</sup> ; Pfizer Inc. <sup>1,5</sup> ; Roche Pharmaceuticals <sup>1</sup> ; Solvay Pharmaceuticals, Inc. <sup>1</sup> ; Wyeth-Ayerst Laboratories <sup>1</sup>
Shimi Kang, M.D.	Alkermes, Inc. <sup>1,5</sup> ; AstraZeneca Pharmaceuticals LP <sup>5</sup> ; Cephalon, Inc. <sup>5</sup> ; Eli Lilly and Company <sup>5</sup> ; Janssen Pharmaceutica Products, LP <sup>5</sup>
Shitij Kapur	Forest Laboratories, Inc. <sup>5</sup> ; Schwartz Pharma <sup>5</sup>
Wayne J. Katon, M.D.	Eli Lilly and Company <sup>4</sup> ; Forest Laboratories, Inc. <sup>4</sup> ; GlaxoSmithKline <sup>5</sup> ; John A Hartford Foundation <sup>3</sup> ; National Institute of Mental Health <sup>3</sup> ; Wyeth-Ayerst Laboratories <sup>4</sup>
David J. Katzelnick, M.D.	Abbott Laboratories, Inc. <sup>1,3,5</sup> ; AstraZeneca Pharmaceuticals LP <sup>3</sup> ; Forest Laboratories, Inc. <sup>5</sup> ; GlaxoSmithKline <sup>3,5</sup> ; Johnson and Johnson Pharmaceutical Research and Development <sup>6</sup> ; Lilly <sup>5</sup> ; Merck & Co., Inc. <sup>1,3</sup> ; Novartis Pharmaceuticals Corporation <sup>3,5</sup> ; Organon Pharmaceuticals Inc <sup>1</sup> ; Pfizer Inc. <sup>1,3</sup> ; Pharmacia & Upjohn <sup>5</sup> ; Robert Wood Johnson Foundation <sup>1</sup> ; Solvay Pharmaceuticals, Inc. <sup>3</sup> ; Wyeth Pharmaceuticals <sup>1</sup>
Paul E. Keck, M.D.	Abbott Laboratories, Inc. <sup>1,3</sup> ; AstraZeneca Pharmaceuticals LP <sup>1,3</sup> ; Bristol-Myers Squibb Company <sup>1,3</sup> ; Eli Lilly and Company <sup>1,3</sup> ; GlaxoSmithKline <sup>1,3</sup> ; Janssen Pharmaceutica Products, LP <sup>1,3</sup> ; Memory Pharmaceuticals <sup>1</sup> ; Merck & Co., Inc. <sup>3</sup> ; National Institute of Mental Health <sup>3</sup> ; National Institute on Drug Abuse <sup>3</sup> ; Neurocrine Biosciences Inc. <sup>1</sup> ; Organon Pharmaceuticals Inc <sup>3</sup> ; Ortho-McNeil Pharmaceutical, Inc. <sup>1,3</sup> ; Pfizer Inc. <sup>1,3</sup> ; Shire Pharmaceuticals Group plc. <sup>1</sup> ; Stanley Medical Research Institute <sup>3</sup> ; UCB Pharma <sup>3</sup>
George A. Keepers, M.D.	Eli Lilly and Company <sup>5</sup>
Samuel J. Keith, M.D.	AstraZeneca Pharmaceuticals LP <sup>3</sup> ; Bristol-Myers Squibb Company <sup>1,3</sup> ; Cyberonics, Inc. <sup>3</sup> ; Eli Lilly and Company <sup>3</sup> ; Forest Laboratories, Inc. <sup>3</sup> ; GlaxoSmithKline <sup>3</sup> ; Janssen-Cilag <sup>1,3,5</sup> ; Merck, Sharp, and Dohme <sup>3</sup> ; Novartis Pharmaceuticals Corporation <sup>1,3</sup> ; Pfizer Inc. <sup>1,3,5</sup> ; Pharmacia & Upjohn <sup>3</sup> ; Wyeth Pharmaceuticals <sup>3</sup>
John R. Kelsoe, M.D.	GlaxoSmithKline <sup>5</sup> ; Psynomics, Inc. <sup>4</sup>
Ronald C. Kessler, Ph.D.	Bristol-Myers Squibb Company <sup>3</sup> ; Eli Lilly and Company <sup>1,3</sup> ; GlaxoSmithKline <sup>1</sup> ; Ortho-McNeil Pharmaceutical, Inc. <sup>3</sup> ; Pfizer Inc. <sup>1,3</sup> ; Wyeth-Ayerst Laboratories <sup>1</sup>
Terence A. Ketter, M.D.	Abbott Laboratories, Inc. <sup>1,3,5</sup> ; AstraZeneca Pharmaceuticals LP <sup>1,3,5</sup> ; Bristol-Myers Squibb Company <sup>1,3,5</sup> ; Cephalon, Inc. <sup>1</sup> ; Corcept Therapeutics <sup>1</sup> ; Eisai Inc. <sup>3</sup> ; Elan Pharmaceuticals, Inc. <sup>1,3</sup> ; Eli Lilly and Company <sup>1,3,5</sup> ; Forest Laboratories, Inc. <sup>1</sup> ; GlaxoSmithKline <sup>1,3,5</sup> ; Janssen Pharmaceutica Products, LP <sup>1,3,5</sup> ; Jazz Pharmaceuticals, Inc. <sup>1</sup> ; Merck & Co., Inc. <sup>1</sup> ; Novartis Pharmaceuticals Corporation <sup>1,3,5</sup> ; Pfizer Inc. <sup>5</sup> ; Shire Pharmaceuticals Group plc. <sup>1,3,5</sup> ; Solvay Pharmaceuticals, Inc. <sup>1,3</sup> ; UCB Pharma <sup>1</sup> ; Wyeth Pharmaceuticals <sup>1,3</sup>
Sabrina J. Khan, M.D.	Eli Lilly and Company <sup>6</sup> ; Merck & Co., Inc. <sup>6</sup> ; Pfizer Inc. <sup>6</sup> ; Schering-Plough Corporation <sup>6</sup>
Clinton D. Kilts, Ph.D.	Forest Laboratories, Inc. <sup>1,3</sup> ; H. Lundbeck A/S <sup>1</sup> ; Janssen Pharmaceutica Products, LP <sup>3</sup> ; National Institute of Mental Health <sup>3</sup> ; National Institute on Drug Abuse <sup>3</sup> ; Solvay Pharmaceuticals, Inc. <sup>1</sup>
David G. Kingdon, M.D.	AstraZeneca Pharmaceuticals LP <sup>5</sup> ; Bristol-Myers Squibb Company <sup>5</sup> ; Eli Lilly and Company <sup>4,5</sup> ; Guilford Press <sup>4</sup> ; Janssen-Cilag <sup>5</sup> ; Pfizer Inc. <sup>3</sup>
Herbert D. Kleber, M.D.	Alkermes, Inc. <sup>1</sup> ; Reckitt-Benkiser <sup>1,3</sup>
Harold W. Koenigsberg, M.D.	Janssen Pharmaceutica Products, LP <sup>3</sup>
George F. Koob, Ph.D.	Addex Pharmaceuticals <sup>1</sup> ; Alkermes, Inc. <sup>1</sup> ; Forest Pharmaceuticals, Inc. <sup>1</sup> ; Hythiam Inc. <sup>1</sup>
Lorin M. Koran, M.D.	Cypress Bioscience Inc. <sup>1,6</sup> ; Eli Lilly and Company <sup>3</sup> ; Forest Laboratories, Inc. <sup>3,5</sup> ; Jazz Pharmaceuticals, Inc. <sup>3</sup> ; Ortho-McNeil Pharmaceutical, Inc. <sup>3</sup> ; Somaxon Pharmaceuticals <sup>3</sup>
Thomas R. Kosten, M.D.	Alkermes, Inc. <sup>1</sup> ; Bristol-Myers Squibb Company <sup>1</sup> ; Cephalon, Inc. <sup>1</sup> ; Gerson Lehman Group <sup>1</sup> ; Johnson and Johnson Pharmaceutical Research and Development <sup>1,6</sup> ; Merck, Sharp, and Dohme <sup>1</sup> ; National Institute of Mental Health <sup>3</sup> ; National Institute on Drug Abuse <sup>1,3</sup> ; Novartis Pharmaceuticals Corporation <sup>1</sup> ; Pfizer Inc. <sup>6</sup>
Christopher J. Kratochvil, M.D.	Abbott Laboratories, Inc. <sup>1,3</sup> ; AstraZeneca Pharmaceuticals LP <sup>1</sup> ; Boehringer-Ingelheim Pharmaceuticals <sup>1</sup> ; Cephalon, Inc. <sup>1,3</sup> ; Eli Lilly and Company <sup>1,3,5</sup> ; McNeil Consumer Healthcare <sup>3</sup> ; National Institute of Mental Health <sup>1,3</sup> ; Organon Pharmaceuticals Inc <sup>1</sup> ; Pfizer Inc. <sup>1</sup> ; Shire Pharmaceuticals Group plc. <sup>1,3</sup>
K Ranga Krishnan, M.D.	Abbott Laboratories, Inc. <sup>1</sup> ; Amgen, Inc. <sup>1</sup> ; Bristol-Myers Squibb Company <sup>1</sup> ; CeNeRx <sup>1</sup> ; Cyberonics, Inc. <sup>1</sup> ; Eli Lilly and Company <sup>1</sup> ; GlaxoSmithKline <sup>1</sup> ; H. Lundbeck A/S <sup>1</sup> ; Johnson and Johnson Pharmaceutical Research and Development <sup>1</sup> ; Merck & Co., Inc. <sup>1</sup> ; Novartis Pharmaceuticals Corporation <sup>3</sup> ; NPS Pharmaceuticals <sup>1</sup> ; Organon Pharmaceuticals Inc <sup>1</sup> ; Otsuka America Pharmaceutical, Inc. <sup>1</sup> ; Pfizer Inc. <sup>1</sup> ; Sepracor, Inc. <sup>1</sup> ; Somerset Pharmaceuticals Inc. <sup>1</sup> ; Vela Pharmaceuticals, Inc. <sup>1</sup> ; Wyeth Pharmaceuticals <sup>1</sup>
Meir H. Kryger, M.D.	Cephalon, Inc. <sup>1</sup> ; National Institute of Health <sup>3</sup> ; Takeda Pharmaceuticals America, Inc. <sup>1</sup>
Andrew D. Krystal, M.D.	King Pharmaceuticals, Inc. <sup>1</sup> ; Merck & Co., Inc. <sup>3</sup> ; Neurocrine Biosciences Inc. <sup>1,3</sup> ; Neurogen Corporation <sup>1</sup> ; Pfizer Inc. <sup>1,3</sup> ; Respiroics, Inc. <sup>1,3</sup> ; Sanofi-Aventis <sup>1,3</sup> ; Sepracor, Inc. <sup>1,3</sup> ; Somaxon Pharmaceuticals <sup>1,3</sup> ; Takeda Pharmaceuticals America, Inc. <sup>1</sup>

## DISCLOSURE INDEX

Presenter	Manufacturer(s)
Joyce C. West, Ph.D.	AstraZeneca Pharmaceuticals LP <sup>3</sup> ; Bristol-Myers Squibb Company <sup>3</sup> ; Eli Lilly and Company <sup>3</sup> ; Janssen Pharmaceutica Products, LP <sup>3</sup> ; National Institute of Mental Health <sup>3</sup> ; Substance Abuse and Mental Health Services Administration/ Center for Substance Abuse Treatment <sup>3</sup> ; Wyeth Pharmaceuticals <sup>3</sup>
Timothy E. Wilens, M.D.	Abbott Laboratories, Inc. <sup>1</sup> ; Eli Lilly and Company <sup>3,5</sup> ; GlaxoSmithKline <sup>1</sup> ; Janssen Pharmaceutica Products, LP <sup>1</sup> ; National Institute of Mental Health <sup>1</sup> ; National Institute on Drug Abuse <sup>3</sup> ; NeuroSearch A/S <sup>3</sup> ; Novartis Pharmaceuticals Corporation <sup>5</sup> ; Ortho-McNeil Pharmaceutical, Inc. <sup>3,5</sup> ; Pfizer Inc. <sup>1</sup> ; Saegis <sup>1</sup> ; Sanofi-Aventis <sup>1</sup> ; Shire Pharmaceuticals Group plc. <sup>3,5</sup>
Jeffery N. Wilkins, M.D.	Alkermes, Inc. <sup>1,3</sup> ; CME LLC <sup>1</sup> ; Forest Laboratories, Inc. <sup>3</sup> ; Hythiam Inc. <sup>1,3</sup>
Janet B.W. Williams, D.S.W.	American Psychiatric Press <sup>4</sup> ; Columbia University <sup>2</sup> ; MedAvante, Inc. <sup>1</sup>
Solomon S. Williams, M.D.	Boehringer-Ingelheim Pharmaceuticals <sup>2</sup>
M.E. Jan Wise, M.B.Ch.B.	Bristol-Myers Squibb Company <sup>5</sup> ; Eli Lilly and Company <sup>5</sup>
Thomas N. Wise, M.D.	Eli Lilly and Company <sup>1</sup>
Jesse H. Wright III, M.D.	Mindstreet <sup>4</sup> ; Pfizer, GlaxoSmithKline <sup>5</sup>
Aysegul Yildiz-Yesiloglu, M.D.	AstraZeneca Pharmaceuticals LP <sup>3</sup> ; GlaxoSmithKline <sup>3</sup> ; Janssen-Cilag <sup>3</sup> ; Pfizer Inc. <sup>3</sup>
Monique Yohanan, M.D.	Elan Pharmaceuticals, Inc. <sup>4</sup> ; Johnson and Johnson Pharmaceutical Research and Development <sup>6</sup>
M. Scott Young, Ph.D.	Eli Lilly and Company <sup>3</sup>
Mary C. Zanarini, Ed.D.	Eli Lilly and Company <sup>1,3</sup>
Phyllis C. Zee, M.D.	Kyowa Pharmaceuticals <sup>3</sup> ; Neurocrine Biosciences Inc. <sup>1</sup> ; Pfizer Inc. <sup>1</sup> ; Sanofi-Aventis <sup>1,5</sup> ; Takeda Pharmaceuticals America, Inc. <sup>1,5</sup>
Mark Zimmerman, M.D.	Bristol-Myers Squibb Company <sup>5</sup> ; GlaxoSmithKline <sup>5</sup> ; Wyeth Pharmaceuticals <sup>5</sup>
Sidney Zisook, M.D.	Aspect Medical Systems <sup>3</sup> ; Forest Laboratories, Inc. <sup>5</sup> ; GlaxoSmithKline <sup>1,5</sup> ; National Alliance for Research in Schizophrenia and Depression <sup>3</sup> ; National Institute of Health <sup>3</sup> ; National Institute of Mental Health <sup>3</sup> ; PamLab <sup>3</sup>
Joseph Zohar, M.D.	Lundbeck <sup>3</sup> ; Pfizer Inc. <sup>3</sup>
Edward Zuzarte, M.D.	Pfizer Inc. <sup>5</sup>